Scorpion Capital obefazimod safety allegations drive Abivax ADRs down
- Scorpion Capital published a November 20 short report targeting lead drug obefazimod.
- The report alleged carcinogenicity risks, extreme lipophilicity and unsupported drug science.
- Abivax opened roughly 2% lower, then losses deepened after report circulation.
- The 9.24% decline was nearly twice Abivax's recent average daily range.
- Reuters and Investing.com linked the intraday selloff directly to Scorpion's report.
- Scorpion disclosed a short position and financial interest in Abivax declining.
- Abivax's 4:33 p.m. statement rejected the allegations as inaccurate and misleading.
- The post-close rebuttal confirmed the catalyst but did not cause regular-session losses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.